Data from the 26-week, randomized, double-blind, placebo-controlled study revealed that a statistically significant number of patients on AMG 416 achieved greater than 30% reduction in parathyroid hormone levels compared to patients on placebo (74% versus 8.3%).
In Jul 2014, the company had announced positive data from another phase III study evaluating the efficacy and safety of AMG 416 in CKD patients receiving hemodialysis and suffering from secondary hyperparathyroidism. The study met all its primary and secondary endpoints.
NOT FOR CKD...
Gary and other retail bashing clowns... That is all you need to know. They have over 18 million shares.
I'll stick with the Bakers.
Sentiment: Strong Buy
Exactly how did PIP contribute to the development of ST-246? They provided zero scientific expertise. Hell, they wanted to fire Hruby. They did provide a bridge loan that was paid back with interest. They did nothing that a sophisticated company would do to protect their potential rights to the drug. Although this shortcoming was mentioned in the record, Parsons has yet to hold PIP responsible for their negligence. The only positive thing PIP has done in their existence is file a lawsuit and find a judge looney enough to agree with them.
Thanks Central... I believe you're right about how the chain of events will unfold but of course I'm only speculating. I'm not an Oracle like Parsons.
I knew the PIPsters would not chime in on this. I"ll bet PIP was modeling significant revenue for this product 8 years ago. The reality is they have nothing to show for their time and effort. Valuing an unapproved, experimental drug is pure speculation. That's why the PIP expert provided so many different scenarios in regard to ST-246. Because in reality he did not have a clue but needed to provide enough "data" to collect his fee.
Tell me why PIP has not been able to sell Sparvax. What did that model look like 8 years ago?
So where is the balance in regard to PIP failing to protect their interests? I have yet to see that in any of Parsons actions.
And Golong I hope you and your family are doing well.
If it is that simple it surely isn't reflected in PIP's market cap. There are gaping holes in Parsons' logic. For example, he does not even consider the possibility of toxicity in humans and how that would have impacted any orders, he does not address competitive concerns, there's no mention of the pitfalls of facing a safety audit for manufacturing, he assumes BARDA would be formed and funded and "bad faith" or not he really hasn't punished PIP for "failing to protect their interests." Also, PIP was ready to fire Hruby. How would that have impacted the future?
How this level of incompetence by PIP could be potentially rewarded is beyond the scope of reason.
Hey Richman don't you have an ambulance chasing company to run? You should not spend your whole day posting on Yahoo forums.
The reason the price is parked at $1.80 is real investors do not believe there will be a significant settlement. If there was any conviction the price would be moving substantially higher on large volume.
There are no licensed treatments or vaccines for Ebola. As well as Mapp, several other biotech companies and research teams have been working on potential drugs.
Companies with possible treatments include Tekmira Pharmaceuticals, Biocryst Pharmaceuticals and Siga Technologies.http://finance.yahoo.com/news/backs-experimental-ebola-drugs-west-114535420.html
You should crawl back under your rock. SIGA absolutely can appeal this ruling. You're just pulling stuff out of thin air.
"In coming to its conclusion, the Court reversed its own prior ruling that expectation damages were not recoverable because they were too speculative. The Court's most recent decision now holds that expert testimony from the original trial, which it had previously found to be too speculative, supports an award of expectation damages. William J. Haynes II, SIGA's General Counsel, commented, "While we are not surprised that the Court left undisturbed SIGA's ownership and control of our smallpox drug, we respectfully disagree with the Chancery Court's decision on damages. We believe that aspect of this decision is not supported by the record or the law, and we expect to appeal it to the Supreme Court of Delaware."
That's Hayes saying I'd love to visit "Parsonsland." A place where government unicorns hand out billion dollar contracts and there are no impediments to success. A place where oracles read the future and spin tales of outlandish riches.
This mess was created by his predecessor.